- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04333173
Endovascular Therapy for Erectile Dysfunction (RE-ACTION)
ENDOVASCULAR THERAPY REGISTRY FOR ERECTILE DYSFUNCTION
Brief Summary: Background and pathophysiology Erectile dysfunction is a serious disease with a significant impact on the quality of life. Male erection is a complex mechanism that involves neuro-vascular tissue responses with several phases including arterial dilatation, smooth muscle cells relaxation and ultimately veno-occlusive activation. Vasculogenic erectile dysfunction can be divided in arteriogenic (when there is insufficiency of arterial component of erection due to atherosclerotic plaque encroachment of the penile arteries) or venogenic (where there is insufficiency of the venous component of erection for venous endoleak) Standard treatment Erectile dysfunction is commonly treated by oral phosphodiesterase-5-inhbitor (PDE5i) administration. However, up to 50% of men have a suboptimal response to PDE5-i therapy with the need of additional therapies. New treatment Only recently several studies have been published on percutaneous treatment of ED using POBA, Drug eluting balloons (both paclitaxel and sirolimus, PEB and SES) and drug eluting stents (DES).
Aim of the study The study was aimed at evaluating both arteriogenic and venogenic endovascular treatments in patients affected by erectile dysfunction in an Italian patient cohort.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Novara, Italy
- Centro Cuore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years old
- Be able to understand and sign a witnessed informed consent for the procedure
- Eligibility for percutaneous peripheral intervention
- Baseline IIEF-5 score evaluation < 15
- PSV < 25 cm/sec
- Stable hemodynamic conditions
- Normal ejection fraction
- Being refractory to oral PDE5-I for at least 6 months before enrollement
- Treatable angiographic lesions of the pudendal arteries
Exclusion Criteria:
- Heart failure
- Hemodynamic instability
- Basal IIEF-5 and doppler examination
- Blood count not within normal ranges
- No history of bleeding or coagulopathy
- No other serious medical illness
- Other investigational drug or device study
- Pudendal artery < 1.5 mm and lesion lenght greater than 80 mm by visual estimation
- Pudendal restenosis from previous intervention
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Active endovascular treatment
Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment
|
Endovascular therapies for erectile dysfunction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IEF-5 SCORE VARIATION AFTER ENDOVASCULAR
Time Frame: 6 months
|
INTERNATIONAL INDEX OF ERECTILE FUNCTION
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSV VARIATION AFTER ENDOVASCULAR TREATMENT
Time Frame: 6 month
|
PUDENDAL DOPPLER PEAK SYSTOLIC VELOCITY
|
6 month
|
ADVERSE EVENTS
Time Frame: 6-12 months
|
Procedural complications; cardiovascular events during follow-up
|
6-12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sangiorgi G, Colantonio R, Antonini G, Savino A, Sperandio M. [Percutaneous intervention therapy for vascular erectile dysfunction]. G Ital Cardiol (Rome). 2016 Oct;17(10 Suppl 1):12S-21. doi: 10.1714/2372.25474. Italian.
- Doppalapudi SK, Wajswol E, Shukla PA, Kolber MK, Singh MK, Kumar A, Fischman A, Rastinehad AR. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. J Vasc Interv Radiol. 2019 Aug;30(8):1251-1258.e2. doi: 10.1016/j.jvir.2019.01.024. Epub 2019 May 17.
- Diehm N, Marggi S, Ueki Y, Schumacher D, Keo HH, Regli C, Do DD, Moeltgen T, Grimsehl P, Wyler S, Schoenhofen H, Raber L, Schumacher M. Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. J Endovasc Ther. 2019 Apr;26(2):181-190. doi: 10.1177/1526602819829903. Epub 2019 Feb 11.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
-
Vancouver Coastal HealthRecruitingSituational Erectile DysfunctionCanada
Clinical Trials on endovascular procedure
-
TherenvaCH LibourneCompletedPeripheral Arterial DiseaseFrance
-
TherenvaCentre Hospitalier Universitaire Dijon; University Hospital, Brest; Rennes University... and other collaboratorsUnknownAortic Aneurysm | Iliac Artery Stenosis | Iliac Aneurysm | Stenoses, AorticFrance
-
Scitech Produtos Medicos LtdaWithdrawnCardiovascular Diseases | Abdominal Aortic AneurysmBrazil
-
Corindus Inc.CompletedHeadache | Subarachnoid Hemorrhage | Intracranial AneurysmCanada, Spain, Australia, Switzerland, Austria, France
-
Liverpool University Hospitals NHS Foundation TrustCompletedPeripheral Arterial DiseaseUnited Kingdom
-
Lombard MedicalCompletedAbdominal Aortic AneurysmCzech Republic, Germany, Poland, Spain, United Kingdom
-
Sohag UniversityRecruitingWide Neck Saccular Cerebral AneurysmsEgypt
-
Clinica San GaudenzioRecruitingErectile DysfunctionItaly
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
University of Alabama at BirminghamWithdrawnVentricular Fibrillation | Ventricular Tachycardia | Cardiac Arrest, Out-Of-HospitalUnited States